Severe COVID-19-associated myocarditis with cardiogenic shock - management with assist devices - a case report & review

  • Stephanie Noone (Shared first author)
  • Armin N Flinspach (Shared first author)
  • Stephan Fichtlscherer
  • Kai Zacharowski
  • Michael Sonntagbauer (Shared last author)
  • Florian J Raimann (Shared last author)

Abstract

BACKGROUND: Primary viral myocarditis associated with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) infection is a rare diagnosis.

CASE PRESENTATION: We report the case of an unvaccinated, healthy patient with cardiogenic shock in the context of a COVID-19-associated myocarditis and therapy with simultaneous veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and percutaneous left ventricular decompression therapy with an Impella. The aim of this review is to provide an overview of therapeutic options for patients with COVID-19-associated myocarditis.

CONCLUSIONS: The majority of patients required a combination of two assist devices to achieve sufficient cardiac output until recovery of left ventricular ejection fraction. Due to the rapid onset of this fulminant cardiogenic shock immediate invasive bridging therapy in a specialized center was lifesaving.

Bibliographical data

Original languageEnglish
Article number385
ISSN1471-2253
DOIs
Publication statusPublished - 12.12.2022
Externally publishedYes

Comment Deanary

© 2022. The Author(s).

PubMed 36503438